MDNAF
Medicenna Therapeutics Corp

1,011
Loading...
Loading...
News
all
press releases
News Placeholder
Medicenna Therapeutics (MDNAF) Upgraded to Buy: Here's What You Should Know
Medicenna Therapeutics (MDNAF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·16h ago

Latest MDNAF News

View

Advertisement. Remove ads.

Advertisement. Remove ads.